Hookipa Pharma (NASDAQ:HOOK – Get Free Report) had its price target lowered by research analysts at HC Wainwright from $6.50 to $5.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Separately, Royal Bank of Canada restated an “outperform” rating and […]
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) had its target price decreased by investment analysts at HC Wainwright from $6.50 to $5.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Separately, Royal Bank of Canada reaffirmed an “outperform” rating and […]
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or.
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority.